On Friday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced it had launched a generic Axiron topical solution CIII in the United States. The testosterone topical solution requires a prescription and is utilized to treat low and no testosterone in adult males. The medication is available in a metered dose pump and is applied using a underarm applicator. Teva has committed itself to strengthening its generic business by investing in complex, high-quality products.

Teva is currently the holder of the largest portfolio of FDA-approved generic products. Approximately one in six generic prescriptions in the United States is filled with a Teva medication. The company has nearly 600 generic medications available. The topical solution CIII is designed for replacement therapy in male patients suffering from a deficiency or absence of endogenous testosterone.

During clinical trials, it was discovered that the most common adverse reactions associated with the medication were site reactions, headache, diarrhea, vomiting, increase hematocrit, and increased serum prostate specific antigen.